Combining antibiotics seems like a logical procedure. When fighting two different or particularly virulent infections, your instinct is to intensify your efforts. This approach is called combination therapy and is the standard of care for chronic, complex diseases. It is a treatment for HIV/AIDS, cancer, malaria and tuberculosis. The goal is simple. Use multiple medications to kill pathogens and reduce the risk of developing resistance.
Antibiotic resistance is a major global health crisis. It is reasonable to assume that the logic of HIV also applies to bacterial infections. However, this assumption can be dangerously wrong.
An important study in 2013 questioned this doctrine. Researchers have found that mixing antibiotics not only slows down drug resistance; it actively accelerates it. Research shows that our current prescribing habits are not enough to curb the rate of growth of drug-resistant bacteria. In fact, the data suggest that using these drugs together can lead to significantly worse outcomes than using either drug alone.
Experiments that shocked scientists
The study was carried out by evolutionary biologists from the University of Exeter in Great Britain and the University of Kiel in Germany. Their goal was to see how quickly E. coli bacteria can adapt to drug pressure.
They designed two control experiments. One group received one antibiotic treatment. Another group received a combination of erythromycin and doxycycline. This combination is considered very effective.
Preliminary results are promising. During the first 24 hours, the combination treatment crushed the bacterial population. E. coli levels dropped by 95%. Looks like we’re winning.
But the data took a sharp turn. Within 24 hours of the initial drop, the bacterial counts increased by 500%. The researchers were very concerned about the rapid rebound and suspected experimental error. They thought the sample was contaminated. They reset the test. The result happened again.
Within five days, the combination treatment was no longer effective. Bacteria are widespread and clearly outpacing the growth seen in the single-drug groups.
How quickly antibiotic resistance develops
The mechanism behind this reversal is clear. This powerful combination wiped out the vulnerable majority of the E. coli population. left only the 5 percent that were naturally resilient.
This small group of survivors faces immense pressure to survive. This is a fight for survival. Under such intense pressure, bacteria did not just survive. They adapted aggressively.
Within a day of the first treatment, the surviving bacteria had replicated their genes. They developed four different new ways to resist the antibiotics. Bacteria from single-treatment samples were not exposed to the same selection pressure. They don’t need to mutate as rapidly or as radically to survive. This is an example of “what doesn’t kill you makes you stronger” at work on an evolutionary level.
Impact on medical practice
The medical community has long warned about drug-resistant bacteria. The findings suggest that the threat is more serious than previously thought. We have consistently underestimated the adaptability of these pathogens.
If this research holds true, antibiotic combination therapy may not be a wise way to treat known drug-resistant strains. This includes E. E. coli and methicillin-resistant Staphylococcus aureus* (MRSA). Strategies that work for viruses like HIV may not work for bacteria.
The authors of this study believe that alternating therapy (switching between different medications) may be a more effective strategy. This approach prevents strong selection pressures that would cause rapid mutations. However, they warn that there is definitive research is still lacking. We need more data before changing the standard protocol.
The gap between current treatment models and bacterial evolution is growing. Until we close it, the belief that “more is better” may be fueling the very crisis we are trying to prevent.
